Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Tumor Progression02:07

Tumor Progression

Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
Tumor Progression02:07

Tumor Progression

Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Deciphering small sequence differences in T cell receptor-antigen pairing.

Nature communications·2026
Same author

Association of PD-L1 expression with systemic immune parameters in non-small cell lung cancer.

Translational lung cancer research·2025
Same author

Factors Associated With Male Breast Cancer Incidence Among Prostate Cancer Survivors: Real World Evidence From Veterans Affairs National Prostate Cancer Data Core.

The Prostate·2025
Same author

Osimertinib plus consolidative radiotherapy for advanced <i>EGFR</i> mutant non-small cell lung cancer: a multicentre, single-arm, phase 2 trial.

EClinicalMedicine·2025
Same author

Profiling antigen-binding affinity of B cell repertoires in tumors by deep learning predicts immune-checkpoint inhibitor treatment outcomes.

Nature cancer·2025
Same author

Concurrent and Consolidative Carboplatin Plus Nab-Paclitaxel or Paclitaxel in Locally Advanced NSCLC: A Multicenter, Randomized Clinical Trial.

International journal of radiation oncology, biology, physics·2025

Related Experiment Video

Updated: Jun 17, 2026

Detection of Targetable Alterations in Non-small Cell Lung Cancer using Next-generation Sequencing
05:17

Detection of Targetable Alterations in Non-small Cell Lung Cancer using Next-generation Sequencing

Published on: October 10, 2025

Small cell lung cancer: are we making progress?

Jonathan E Dowell1

  • 1Hematology/Oncology, Veterans Affairs North Texas Healthcare System, Dallas, Texas, USA. jonathan.dowell@utsouthwestern.edu

The American Journal of the Medical Sciences
|December 10, 2009
PubMed
Summary

Small cell lung cancer (SCLC) remains a deadly disease, with limited treatment advances for extensive stages. New molecular targets offer hope for improved therapies in the future.

Related Experiment Videos

Last Updated: Jun 17, 2026

Detection of Targetable Alterations in Non-small Cell Lung Cancer using Next-generation Sequencing
05:17

Detection of Targetable Alterations in Non-small Cell Lung Cancer using Next-generation Sequencing

Published on: October 10, 2025

Area of Science:

  • Oncology
  • Pulmonology
  • Cancer Research

Background:

  • Small cell lung cancer (SCLC) incidence has decreased but remains a major cause of cancer mortality globally.
  • While limited-stage SCLC has a cure rate of approximately 20%, outcomes for extensive-stage disease are poor.
  • Therapeutic progress for extensive-stage SCLC has been minimal, with prophylactic cranial irradiation being a recent, modest advance.

Purpose of the Study:

  • To review the current state of small cell lung cancer (SCLC) treatment and outcomes.
  • To highlight the limited progress in enhancing traditional chemotherapy for SCLC.
  • To explore emerging molecular targets and their potential for future SCLC therapies.

Main Methods:

  • Review of existing literature on small cell lung cancer (SCLC) treatment modalities.
  • Analysis of survival data and treatment outcomes for limited and extensive stage SCLC.
  • Examination of recent advancements in understanding SCLC biology and molecular targets.

Main Results:

  • SCLC continues to be a significant cause of cancer death worldwide.
  • Few therapeutic advances have been made for extensive-stage SCLC in recent decades.
  • Despite initial setbacks, novel molecular targets show promise for future SCLC treatment strategies.

Conclusions:

  • Significant improvements in small cell lung cancer (SCLC) therapy are needed, particularly for extensive-stage disease.
  • Understanding SCLC biology has identified new molecular targets for therapeutic development.
  • Emerging targeted therapies hold promise for improving outcomes in this challenging cancer.